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Abstract
Thanks to the development of several new
researches, the lifetime presented a signifi-
cant increase, even so, we still have many
obstacles to overcome − among them, manage
and get responses regarding neurodegenera-
tive diseases. Where we are in the understand-
ing of neuroprotection? Do we really have pro-
tective therapies for diseases considered
degeneratives such as amyotrophic lateral
sclerosis and its variants, Parkinson’s disease,
Alzheimer’s disease and many others?
Neuroprotection is defined by many research-
es as interactions and interventions that can
slow down or even inhibit the progression of
neuronal degeneration process. We make
some considerations on this neuroprotective
effect. 
Some considerations
Time is relentless and cruel, although it is
often helpful to understand live. Search for
strategies to avoid the wear it produces in our
brain machinery, is undoubtedly distressing;
considering that every second corresponds to a
second that does not return. In the early histo-
ry of humankind the average life was reduced
due to its fragility in the face of diseases and
especially of the strongest predators. With the
development of research in Medicine, lifetime
presented a significant increase; yet we still
have many hurdles to overcome − among them
manage and get responses regarding neurode-
generative diseases. With aging we lost cells,
the cell division mechanism becomes slowed,
DNA mutations tend to occur (disorienting the
cell command), the energy supply by mitochon-
drial damage is affected, etc. Cytoplasmic
inclusions and protein aggregates form a non-
degradable brain trash, and relationship with
environmental factors is still unclear, among
other factors.1,2 Fortunately medicine is
improving every day and it tries to respond to
such mechanisms.
We assume to treat that term alone, as well
as the criticism of our colleagues. It is insane
to talk in neuroprotection without mentioning
pathophysiology. In fact, what do we mean by
neuroprotection? Do we really have protective
therapies for example, for diseases such as
amyotrophic lateral sclerosis (ALS) and its
variants, Parkinson’s disease, Alzheimer’s dis-
ease and cerebellar ataxias? Many authors
define neuroprotection as interactions and
interventions that can slow down or even
inhibit the progression of neuronal degenera-
tion.3 In this context it scares us our small/pri-
mate knowledge about the pathophysiological
framework of these diseases. The pathophysi-
ology is broad and interconnected. It takes us
to a puzzle with pieces that do not end, either
fit together and seems to be lacking. When the
model appears to be fitting together, a new
breakthrough appears and everything is
undone. So far, neuroprotective therapies for
neurodegenerative diseases are just theoreti-
cal, awaiting further researches, mainly
through gene mapping. We are sure that after
this provocative communication thousands of
criticism will be raging like wildfire. This is
the science. Even in the double blind studies,
controlled and randomized, that try to fit
patients at the same stage of disease with all
caution, introducing new drugs and monitor
the natural history of the disease by well-
defined periods and instruments, there is a
flaw − the individuality of the human being.
Why do some patients in our clinic have sur-
vival of 20 or more years of clinical and electro-
physiological diagnosis of ALS? Why do indi-
viduals with progressive spinal amyotrophy,
sporadic adult form, have an overwhelming
presentation of the disease that causes death
in months? There are certainly new neuropro-
tective mechanisms, obscure and built into
each one of us.4,5 Stephen William Hawking,
for example, when received the diagnosis of
ALS, was advised not to hold his time with a
book he was writing because he had no life-
time. The physicist not only finished that book,
as he married and had children. We are cur-
rently following a young man aged 25 with a
diagnosis of progressive spinal amyotrophy
three years after clinical onset.
The reader will probably wonder - how to do
something different then? Today, unfortunate-
ly, it is what fills us and what we have to con-
tribute, as the human being does not come
with an instruction manual, especially when
many of his brain parts are already battered
and are irreplaceable. These diseases are big
icebergs: when the damage hatch in neuronal
network is at least scary. Before that, our cen-
tral nervous system has already tried quietly
and certainly in every way to repair our system.
Neurodegenerative diseases represent one
of the great challenges of the current neuro-
science. Parkinson’s disease, for example,
affects millions of individuals worldwide, and
the number of patients is expected to double
over the next 20 years. It is therefore natural
that Parkinson’s disease is the object of
intense research in order to understand its eti-
ology and develop possible treatment strate-
gies.6,7 It has been recently identified that in
Parkinson’s disease when motor manifesta-
tions occur, about 60-80% of substantia nigra
neurons have already succumbed to the dis-
ease process. Many authors even wonder if the
idiopathic Parkinson’s disease really exists or
in fact, they are similar phenotypes to stories
of different evolution.
In Alzheimer’s disease and other forms of
irreversible dementia, aging is part of a multi-
factorial process. Many studies have pointed to
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autophagy for neuroprotective strategies in
aging and in neurodegenerative diseases such
as this, with a focus on sub-cellular changes
related to cell death.8
Anyway, we will continue fighting to allevi-
ate the suffering of our species, with dedica-
tion, competence and especially medical and
scientific commitment. The evidence-based
medicine helped us a lot, however there is
always someone who does not fit this context.
The individuality of diseases process contin-
ues to be a challenge for neuroprotection.
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